# NCT05983432 (NCT05983432)

> Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05983432
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: SystImmune Inc.
- Conditions: Non Small Cell Lung Cancer; Esophageal Cancer; Small Cell Lung Cancer; Nasopharyngeal Cancer; Head and Neck Squamous Cell Carcinoma; Prostate Adenocarcinoma; Ovarian Cancer; Endometrial Cancer; Cervical Cancer; Triple Negative Breast Cancer
- Interventions: BL-B01D1
- Enrollment: 540
- Primary outcome: Participants with Dose-limiting toxicities
- Primary outcome: Participants with Serious Adverse Events (SAEs) and treatment-emergent adverse events (TEAEs),
- Primary outcome: Participants with abnormal physical examination findings
- Primary outcome: Participants with ability to care for themselves, daily activity, and physical activity
- Primary outcome: Participants with abnormal ECG reading
- Primary outcome: Participants with abnormal lab results
- Primary outcome: To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and two or more recommended doses and schedules for recommended dose expansion (RDEs) of BL-B01D1 in metastatic NSCLC

## Indexed commentary on NCT05983432 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05983432